Antibodies against SARS-CoV and methods of use thereof
The invention provides scFv antibodies and monoclonal antibodies that neutralize SARS-CoV. Also provided are methods of treating and/or preventing a coronavirus-related disease or disorder such as SARS. The invention also provides methods of vaccinating a patient against SARS-CoV. Also provided are methods of diagnosing coronavirus-related diseases or disorders and methods of detecting the presence of a coronavirus in a sample. The invention additionally provides methods of screening for compounds that modulate the binding of SARS-CoV and the SARS-CoV receptor ACE2 as well as for compounds useful to treat SARS-CoV-related diseases or disorders.
1. A monoclonal antibody which neutralizes SARS-CoV, wherein said monoclonal antibody binds to an epitope on the spike protein (S) of SARS-CoV consisting of amino acids 324 to 503, wherein the antibody neutralizes SARS-CoV, and wherein said monoclonal antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 12 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 20.
2. A monoclonal antibody which neutralizes SARS-CoV, wherein said monoclonal antibody binds to an epitope on the spike protein (S) of SARS-CoV consisting of amino acids 324 to 503, wherein the antibody neutralizes SARS-CoV, and wherein said monoclonal antibody comprises the amino acid sequences encoded by the nucleotide sequences of SEQ ID NOs: 2, 3, 4, and 5.
3. An scFv antibody which neutralizes SARS-CoV, wherein said scFv antibody binds to an epitope on the spike protein (S) of SARS-CoV consisting of amino acids 324 to 503, wherein said scFv antibody neutralizes SARS-CoV, and wherein said scFv antibody comprises the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1.
4. A monoclonal antibody which neutralizes SARS-CoV, wherein said antibody has a light chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of RASQVRSNLA (SEQ ID NO:37); DASTAT (SEQ ID NO:38); and QQRSNWPPT (SEQ ID NO:39), and wherein said antibody has a heavy chain with three CDRs comprising an amino acid sequence selected from the group consisting of the amino acid sequences of AH; VYDNK (SEQ ID NO: 35); and RSYYL (SEQ ID NO:36).